TheNewsCenter45m
A needleless alternative to Epi-pen is now available for the first time in 100 years
NASHVILLE, Tenn. ( WSMV /Gray News) - For the first time in more than a hundred years, there’s now an FDA-approved ...
No-Moat UCB Focuses on Expanding Disease Indications for Bimzelx as Generics Weigh on Portfolio
We think UCB is in good financial health, with solid earnings and cash flow generation. UCB has deleveraged over the years, and it ended 2023 with about EUR 2.2 billion in net debt on its balance ...